



















- tocilizumab. *Proc Natl Acad Sci USA*. 2020;117(20):10970-5.
63. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev* 2020;19(7):102568.
  64. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol*. 2020;38(3):529-32.
  65. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med* 2020;76:43-9.
  66. Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. *Med Mal Infect*. 2020;50(5):397-400.
  67. Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh M, Altannir M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. *Clin Microbiol Infect*. 2020;[Epub ahead of print]. doi: 10.1016/j.cmi.2020.10.036.
  68. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, Marca SL, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. *Ann Rheum Dis* 2020;79(10):1277-85.
  69. Benucci M, Giannasi G, Cecchini P, Gobbi F, Damiani A, Grossi V, et al. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. *J Med Virol*. 2020;92(11):2366-70.
  70. Montesarchio V, Parrela R, Iommelli S, Bianco A, Manzillo E, Fraganza A, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. *J Immunother Cancer*. 2020;8(2):e001089.
  71. Laurence J, Mulvey J, Meshadri M, Kacanek A, Harp J, Schenck EP, et al. Anti-complement C5 therapy with eculizumab in the cases of critical COVID-19. *Clin Immunol* 2020;197:108555.
  72. Annane D, Heming N, Grimaldi-Bensouda L, Frémeaux-Bacchi V, Vigan M, Roux AL, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. *EClinicalMedicine*. 2020;28:100590.
  73. Atal S, Fatima Z, Balakrishnan S. Approval of itolizumab for COVID-19: A premature decision or need of the hour? *BioDrugs*. 2020;34(6):705-11.
  74. Díaz Y, Ramos-Suzarte M, Martín Y, Calderín J, Santiago W, Viñet O, et al. Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19. *Gerontology*. 2020;66(6):553-61.
  75. fda.gov [Internet]. Food and Drug Administration. US Anakinra label, May 2016. [Cited: 2020 December 14]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/103950s5175lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103950s5175lbl.pdf).
  76. Singh JA, Hossain A, Binjoo Ghoshmu E, Kotb A, Christensen R, Madan AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying antirheumatic drugs: a systematic review and network meta-analysis. *Cochrane Database Syst Rev*. 2016;5:CD011202.
  77. Canna SW, Bousens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. *Pediatr Clin North Am*. 2012;59(2):329-44.
  78. Gellera L, Lipsker D. Schnitzler Syndrome: a review. *Curr Rheumatol Rep*. 2017;19(8):46.
  79. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. *Lancet Rheumatol*. 2020;2(7):e393-400.
  80. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol*. 2020;2(6):e325-31.
  81. Navarro-Millán I, Sattui SE, Laxhanpal A, Zisa D, Siegel CH, Crow MK. Use of anakinra to prevent mechanical ventilation in severe COVID-19: A case series. *Arthritis Rheumatol*. 2020;72(12):1990-7.